-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compilenewborn
The rapid growth of Biohaven's oral migraine drug Nurtec ODT has put tremendous pressure on competitors' migraine preventive drugs
Last weekend, Eli Lilly announced the initiation of a phase 4 clinical trial to compare its monthly subcutaneous CGRP migraine drug Emgality with oral tablets Nurtec ODT for the preventive treatment of paroxysmal migraine (EM)
The new trial called Challenge-MIG plans to enroll about 700 adult patients in the United States, and each patient can participate for up to 6 months
Eli Lilly said that the trial aims to demonstrate superiority and is expected to be completed in the fourth quarter of 2022
Thanks to the FDA's dual approval for acute treatment and preventive treatment of migraine, Nurtec ODT has been on a track of rapid growth
In addition to revenue growth, Nurtec ODT's market share is also increasing
In a recent survey of primary care doctors conducted by Piper Sandler, 65% of doctors agreed that Nurtec ODT's dual indications provide convenience and simplicity for patients
In addition, more than half of the neurologists surveyed by Piper Sandler pointed out that between monthly doses, the effect of antibody drugs is weakened
At the same time, injections such as Emgality are now facing more oral competition
Reference source: Eli Lilly, under pressure from Biohaven, launches head-to-head migraine trial between Emgality and Nurtec
